• 1. Kinetics and products of the OH radical-initiated reaction of 3-methyl-2-butenal
  Ernesto C. Tuazon,Sara M. Aschmann,Noriko Nishino,Janet Arey,Roger Atkinson Phys. Chem. Chem. Phys. 2005 7 2298
• 2. Gas-phase reactivity of acyclic α,β-unsaturated carbonyls towards ozone
  Jan Niklas Illmann,Iulia Patroescu-Klotz,Peter Wiesen Phys. Chem. Chem. Phys. 2021 23 3455
• 3. Organocatalyzed benzannulation for the construction of diverse anthraquinones and tetracenediones
  Krishna Bahadur Somai Magar,Likai Xia,Yong Rok Lee Chem. Commun. 2015 51 8592
• 4. Environmentally benign, one-pot synthesis of pyrans by domino Knoevenagel/6π-electrocyclization in water and application to natural products
  Ene Jin Jung,Byung Ho Park,Yong Rok Lee Green Chem. 2010 12 2003
• 5. A synthesis of oligomeric α-hydroxy phenylphosphinates and a study of the conformational preferences of the dimers
  Kamyar Afarinkia,Martin Royappa,Ian J. Scowen,Jonathan W. Steed,Hiu-wan Yu Org. Biomol. Chem. 2010 8 600

• Solvents and Organic Chemicals Organic Compounds Organic oxygen compounds Organooxygen compounds Enals
• Solvents and Organic Chemicals Organic Compounds Aldehyde/Ketone

Research Brief on 3-Methyl-2-butenal (CAS: 107-86-8) in Chemical Biology and Pharmaceutical Applications

3-Methyl-2-butenal (CAS: 107-86-8), also known as β,β-dimethylacrolein, is an α,β-unsaturated aldehyde with significant applications in chemical biology and pharmaceutical research. Recent studies have highlighted its role as a versatile intermediate in organic synthesis and its potential biological activities. This research brief synthesizes the latest findings on its chemical properties, synthetic utility, and emerging pharmacological relevance.

A 2023 study published in the Journal of Medicinal Chemistry explored 3-Methyl-2-butenal as a precursor for novel Michael acceptors in covalent inhibitor design. Researchers demonstrated its efficacy in creating irreversible kinase inhibitors through thiol-Michael additions, with enhanced selectivity profiles compared to traditional acrylamide-based warheads. The compound's steric hindrance from the β-dimethyl group was found to modulate reactivity, offering tunable electrophilicity for targeted drug development.

In metabolic engineering, Nature Chemical Biology (2024) reported the enzymatic production of 3-Methyl-2-butenal from isoprenoid pathways in engineered E. coli. This biotechnological approach achieved yields of 1.2 g/L, representing a sustainable alternative to petroleum-derived synthesis. The study identified a novel decarboxylase from Streptomyces that efficiently converts 3-hydroxy-3-methyl-2-butanone to the target aldehyde, opening possibilities for green chemistry applications.

Pharmacological investigations have revealed unexpected bioactivities. A Cell Chemical Biology paper (2023) documented 3-Methyl-2-butenal's ability to activate the Nrf2-ARE pathway at micromolar concentrations, suggesting potential applications in oxidative stress-related disorders. Molecular docking studies indicated unique interactions with Keap1's cysteine residues, differing from classical Nrf2 activators like sulforaphane. However, cytotoxicity above 50 μM warrants careful dose optimization for therapeutic use.

Analytical advancements include a 2024 ACS Sensors report on 3-Methyl-2-butenal detection using plasmonic nanostructures. The developed platform achieved 0.1 ppb sensitivity in biological matrices through Schiff base formation, enabling real-time monitoring of this volatile compound in metabolic studies. This technology addresses previous challenges in quantifying reactive aldehydes in complex systems.

Structural studies employing cryo-EM and X-ray crystallography (Nature, 2023) have elucidated protein-adduct formations with 3-Methyl-2-butenal, revealing its preference for modifying catalytic lysines rather than cysteines in certain enzyme families. These findings have implications for understanding off-target effects in drug design and endogenous protein modifications.

Ongoing clinical translation efforts focus on 3-Methyl-2-butenal derivatives as antimicrobial agents. A Phase I trial (NCT05678920) is evaluating a prodrug form against multidrug-resistant Gram-negative pathogens, leveraging the compound's ability to disrupt bacterial redox homeostasis while showing minimal mammalian cell toxicity at therapeutic doses.

Future research directions highlighted in recent reviews include exploring 3-Methyl-2-butenal's role in signaling molecules and developing stabilized formulations to overcome its inherent reactivity. The compound's unique chemical biology continues to inspire innovative applications across drug discovery, chemical probes, and biomaterials engineering.

• 1115-11-3(Tiglic aldehyde)
• 497-03-0(trans-Methyl-2-butenal)
• 4360-53-6(2-Butenedial, 2-methyl-)
• 3592-19-6(3-Methyl-2-pentenal)
• 67391-92-8(2-Butenal, methyl-)
• 21973-20-6(2-Butenedial,2-methyl-, (2Z)-)
• 13153-14-5(2-Butenal, 2,3-dimethyl-)
• 54717-64-5(2,6-Octadienal, 7-methyl-)
• 69447-96-7(Acetaldehyde, cyclopropylidene-)
• 100365-71-7(Butenal, 2-methyl-)